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Herpes Zoster Encephalitis: Successful Therapy with Vidarabinet
Steven J. Wees, M D * and Tom Madhavan, MD''
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H e r p e s z o s t e r is a c o m m o n i n f e c t i o n in i m m u n o c o m p r o m i s e d and d e b i l i t a t e d e l d e r l y patients and is life
threatening in its visceral disseminated f o r m . Fortunately, a
recent c o l l a b o r a t i v e antiviral study (1) by the N a t i o n a l
Institute of A l l e r g y and Infectious Diseases has s h o w n that
accelerated clearance o f virus f r o m the vesicles, cessation
of n e w vesicle f o r m a t i o n , and a shorter t i m e to total
pustulation results w h e n herpes zoster is treated w i t h intravenous v i d a r a b i n e (adenine arabinoside, ara-A). H o w e v e r ,
w h i l e this d r u g shows promise for therapy in i m m u n o c o m promised patients, its efficacy has not been established in
patients w i t h the visceral c o m p l i c a t i o n s o f encephalitis and
p n e u m o n i t i s . Taber, et al reported no apparent benefit o f
vidarabine therapy in five patients w f t h c l i n i c a l e n c e p h a litis secondary to herpes zoster (2). Contrary to this report,
w e have recently had good c l i n i c a l results using intravenous v i d a r a b i n e to treat a patient w i t h herpes zoster
encephalitis c o m p l i c a t i n g t r i g e m i n a l herpes zoster.

As a result of parenteral
recovered.

vidarabine

and congenital ovalocytosis. Her medications on admission were
insulin, furosemide, digoxin, and folic acid. She had no recent or
past history of alcohol abuse. One day before admission, she
noted blisters near her right eye and began to complain of
excruciating pain there. She was nauseated and vomited several
times the day before she was admitted.
On admission, the patient was somnolent but arousable. She had
no muscle weakness, tonic-clonic movements, or incontinence.
Her temperature was 36°C, the blood pressure 140/70 mm Hg,
and the respiratory rate was 20/mt. Hemorrhagic vesicles were
noted primarily in the right first trigeminal dermatome and, to a
lesser extent, on the right second trigeminal dermatome, and on
the hard and soft palate bilaterally. The right upper and lower lids
were moderately swollen, and numerous vesicles were present. A
mucoid discharge was seen between the lids. The conjunctiva and
cornea appeared free of inflammation, and the pupils were round,
reactive to light, and pinpoint. The fundi could not be visualized.
The patient had several soft anterior cervical nodes and slight
nuchal rigidity Chest auscultation revealed bilateral inspiratory
rales. The apical heart rate was 120/mt and intermittently irregular. There was generalized cardiomegaly; an S3 gallop and lll/VI
systolic murmur were heard at the apex with radiation to the left
axilla. The liver edge was palpable 6 cm below the right costal
margin. The patient's hands showed chronic deformities of rheumatoid arthritis without acute synovitis.

Case Report
A 77-year-old black woman was admitted to Henry Ford Hospital
after experiencing four days of pain and burning in the right
periorbital region. She had diabetes mellitus with chronic renal
failure, quiescent rheumatoid arthritis, congestive heart failure
secondary to arteriosclerotic heart disease, mitral regurgitation,

The patient followed simple commands well, and was oriented to
time, place and person, but could not provide other useful
information. Her cranial nerves were normal, and her motor
function was intact. Deep tendon reflexes could not be elicited,
except for 1 -(- biceps jerks bilaterally. Babinski sign was negative.
No grasp or snout reflexes were noted.
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At admission, the results of her laboratory tests were hemoglobin
7.6 gm%, WBC count 4,600 with 78% poly, 1% bands, 18%
lymphocytes and 3% monocytes, BUN 68 mg%, creatinine 4.7
mg%, calcium 8.3 mg, phosphate 6.8 mg%. The rest o f t h e tests
were within normal limits.

* Department of Internal Medicine, Division of Infectious Diseases, Henry
Ford Hospital
Address reprint requests to Dr. Madhavan, Department of Internal Medicine, Henry Ford Hospital, 2799 W Grand Blvd, Detroit Ml 48202

67

Wees and Madhavan

We initially believed that the patient had herpes zoster involving
the ophthalmic and maxillary divisions of the right trigeminal
nerve with no eye involvement. Herpetic infection was confirmed
by positive Tzanck smear. An electroencephalogram performed
on the second hospital day revealed a severe diftuse disturbance
of cerebral activity over both the hemispheres with prominent
cortical and subcortical irritability. Cerebrospinal fluid was clear
and colorless on four tests. There were 3-37 cells with 99%
lymphocytes on differential count by cytocentrifuge. CSF protein
ranged from 48-104 mg%, and glucose ranged from 49-125 (with
RBS of 147 and 315, respectively). Gram stain and cultures for
bacteria, tuberculosis, and fungi were negative. On the basis of
the clinical presentation, EEG results, and CSF findings, a diagnosis of herpes zoster encephalitis was made. The patient was
started on vidarabine intravenously on the second hospital day.
Based on her renal function, she received 5 mg/kg/day intravenously for eight days (recommended dose is 15 mg/kg/day for
those with normal renal function). She also received intravenous
phenytoin prophylactically. A computerized axial tomograph
scan of the brain on the fourth hospital day showed marked
widening of the cerebral sulci. The ventricular system was not
enlarged or displaced. An area of decreased density was seen in
the right posterior frontal region without mass effect, compatible
with a localized inflammation.

peripheral nerve involvement, and motor neuropathies
wfth or without muscle paralysis are more commonly seen
in zoster than is encephalftis (4). In varicella, on the other
hand, encephalitis is 25 to 30 times more common than
myelitis. Manifestations of herpes zoster encephalftis may
appear within one week before a cutaneous eruption appears. Most cases occur within two weeks after a rash
appears. Approximately one third of patients with encephalitis manifest a distinct syndrome characterized by ophthalmic zoster and contralateral hemiplegia.
The average age of reported patients was 43, ranging from
four to 74 years, and men outnumbered women approximately two to one. Significant underlying disease was
present in about one sixth of the patients. Headache was
common in all patients, whereas altered states of consciousness were more common in those with diffuse encephalitis. Convulsions and ataxia are rarely present in
patients with ophthalmic zoster and hemiplegia, but are
not uncommon in the other group. The reverse is true of
fever and hemiplegia. An unusually high frequency of
cranial nerve involvement is associated with encephalitis
(one out of three), even when the ophthalmic zoster and
hemiplegia group is excluded. Cerebrospinal fluid findings
include mononuclear pleocytosis ranging from 19 to 440
cells/mm^ wfth moderate elevations of protein in one half
and a normal sugar. Electroencephalograms are usually
diffusely abnormal. Brain scan shows focal areas of increased isotope uptake or an abnormal flow pattern. Arteriograms may show segmental angiitis and numerous
vascular occlusions (on the affected side). Granulomatous
angiitis of intracranial vessels has also been noted at autopsy (4).

After two days of intravenous vidarabine, the patient's mental
status slowly began to improve and continued to do so during her
stay. On the fourth day, she developed myoclonus of the left
upper extremity and a positive Babinski reflex on the left, but
these resolved within the next week. A repeat EEG five days after
treatment with vidarabine showed improvement over the initial
EEG, but a moderate diffuse encephalopathic pattern was still
present, affecting cortical and subcortical structures over both
hemispheres, with minimal emphasis over the right central parietal region. When discharged, the patient was fully oriented and
conversant, able to feed and bathe herself, and to walk with a
cane.

The diffuse encephalitic syndrome carries a 33% mortality
rate (4). However, only one fatal case of ophthalmic zoster
with hemiplegia has been reported in a group of 14 patients, although seven patients had significant sequelae.
Most of the deaths occurred in patients reported before
1947, and this figure may be reduced by the supportive
care available today. Significant sequelae consist of hemiplegia, dementia, ataxia, and aphasia. In most cases, hemiplegia is m i l d and resolves at the time of discharge.
Therefore, in contrast to the high mortality rate associated
with untreated herpes simplex encephalitis (3), most patients wfth herpes zoster encephalitis have a reasonably
good prognosis, although significant sequelae do occur.

Her skin lesions of herpes zoster were treated with Burrow's
solution, and no evidence of secondary infection was seen during
hospitalization. Two days after vidarabine had been started, the
lesions were becoming dry and crusting. Only crusted erosions
and right periorbital edema were present on the fifth day of
treatment. There was no evidence of hepatic, hematologic, or
gastrointestinal side effects.

Discussion
Dissemination of herpes zoster virus may occur to skin and
to viscera and is associated primarily with increased morbidity rather than mortality. The central nervous system can
be involved with localized or disseminated infection, inc l u d i n g t w o c l i n i c a l l y distinct forms of encephalitis,
namely ophthalmic zoster wfth hemiplegia and diffuse
encephalftis (4). As many as 40% of patients wfth uncomplicated zoster show a mild pleocytosis or slightly elevated
protein in the cerebrospinal fluid or both, without any
symptoms or signs of meningftis. Spinal nerve root and

Taber, et al, in a review of eight cases with clinical encephalftis, found that central nervous system symptoms and
signs began soon after dissemination and included obtundation (5 patients), confusion (3), coma (1), hallucinations
(1), and meningismus (2). All eight patients had a mononuclear pleocytosis and elevated protein in the cerebrospi-
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nal fluid, and varicella-zoster (VZ) antibody was detected
also. In one patient, the VZ virus was isolated from the
cerebrospinal fluid. Only five patients received treatment.
They also completed vidarabine therapy without toxicity,
but wfthout apparent benefit. However, starting time and
duration of treatment were not mentioned. Three of five
patients who received treatment died, and two others had a
slow, complicated recovery wfth residual neurological dysfunction. Thus, encephalitis as a complication of disseminated herpes zoster was associated with increased
morbidity. The authors speculated that early treatment of
localized herpes zoster with effective antiviral agents might
well decrease the incidence of encephalitis, thereby reducing mortality. Early recognition and prompt institution of
vidarabine therapy in encephalitis may have a beneficial
effect in patients such as ours.

undertaken in humans seriously infected with herpes simplex virus, varicella-zoster, and cytomegalovirus. Since the
results were generally favorable, large-scale control trials
were made (1,3). Data in two studies strongly support the
usefulness of vidarabine for systemic chemotherapy.
Herpes simplex encephalitis is a potentially fatal disease
when untreated. In a recent double-blind placebo controlled study, Whitley, et al, reported 28 brain biopsy-proved
cases. Among 18 who received vidarabine, the mortality
was 28%. Seven ofthe 10 untreated cases died. The level of
consciousness at the time of therapy was found to be a
significant variable. The dosage recommended at present is
15 mg/kg/day given intravenously in a concentration notto
exceed 0.7 mg/ml, dueto low drug solubility. The low level
of toxicity, coupled with the documented effectiveness of
vidarabine when used early in the course of herpes simplex
encephalitis, suggests that vidarabine should be started
early in patients suspected of having the disease. Therapy
can be terminated in five days in patients lacking virologic
proofof diagnosis. For patients with proven disease, ten
days of therapy is recommended. At these doses, toxic
effects of vidarabine are minimal and consist of nausea and
vomfting, weight loss, weakness and diarrhea. At higher
doses, megaloblastosis of bone marrow, SCOT elevation,
tremors, and thrombophlebftis at the intravenous site may
occur. However, all ofthese adverse reactions are reversible.

The pathogenesis of encephalitis associated with zoster is
not clear. Direct viral invasion of spinal cord and brain in
two severely immunosuppressed patients wfth zoster was
presumed after intranuclear inclusions and herpes-like particles were found in autopsy material (4). In addftion, the
virus was isolated from the brain of one patient. The
preponderance of zoster involving cranial nerves in cases
of encephalftis also supports direct viral spread as a potential mechanism of pathogenesis. However, histopathologic
studies suggested "postinfectious changes of hemorrhage
and vasculitis." Perivascular demyelination has also been
described as the characteristic lesion of diffuse encephalftis
(4).

A controlled trial of vidarabine in localized and disseminated herpes zoster was carried out by a collaborative
antiviral study group sponsored by the National Instftute of
Allergy and Infectious Diseases (1). All 87 patients received
both drug and placebo during the trial: efther vidarabine
(Group A) or placebo (Group B) during the first five days of
the study, then the opposite regimen for a second five days.
The drug was administered at a dosage of 10 mg/kg given
intravenously over 12 hours. Progress ofthe infection was
monitored daily, and the healing process was assessed by
various parameters. The two study groups had similar
characteristics. In spite of rapid natural healing, those
receiving vidarabine over the first five days had accelerated
clearance of virus from vesicles, cessation of new vesicle
formation, and a shorter time to total pustulation. Factors
modifying the response to therapy included age (virus
clearance was significantly accelerated in patients younger
than 30), underlying disease (patients with reticulo-endothelial neoplasia cleared the virus from lesions at signfficantly accelerated rates), and duration of zoster before
therapy (most effective when administered during the first
six days of disease) (1). However, results of therapy for six
patients with visceral complications of encephalitis and
pneumonftis were not encouraging. Two patients died of

Vidarabine was synthesized in 1960 for use as a potential
cancer agent. Four years later, the drug was shown to have
a broad spectrum of anti-viral activity in tissue culture,
particularly for classic DNA viruses, including herpes simplex, cytomegalovirus, and varicella-zoster virus. It is an
analogue of the purine base adenine. Recent reports of its
success in controlled studies in treating herpes simplex
encephalftis make this an excellent chemotherapeutic
agent recommended for systemic use in a serious virus
infection (4). Although the precise site of drug action
remains undetermined, the primary site appears to be DNA
polymerase.
Animal studies of both its clinical pharmacology and toxicity showed that vidarabine was less toxic and less immunosuppressive than the other two purine analogues used to
treat serious viral infections, namely cytosine arabinoside
and iodoxuridine (5). Pharmacokinetic studies in humans
revealed that, following a single intravenous infusion, good
plasma levels of vidarabine were reached wfthin 30 minutes, then falling over an eight-hour period (half-life 1.5 hrs)
(6). The kidney is the primary site of clearance. Because of
its favorable properties, limited trials of vidarabine were
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unrelated causes after the study was completed. Two others
died shortly after they were enrolled in the study. Both had
received placebo, and their deaths were attributed to zoster. Although results of this study were discouraging for
disseminated visceral zoster, systemic vidarabine therapy
appears promising in patients similar to our patient.

The NIAID colloborative study showed that vidarabine is a
promising drug for therapy in both localized and disseminated cutaneous herpes zoster in immunocompromised
patients and the elderly. The outcome of our case supports
its continued use in zoster encephalftis with an ongoing
evaluation of its efficacy.
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